MedTrace Logo

Family Perspectives:Treatment of Psychiatric Illnesses With Atypical Long Acting Injectable Antipsychotic Medication

NCT00287027 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2007-01-05

No results posted yet for this study

Summary

Patients who have schizophrenia, schizoaffective disorder, a psychotic disorder, and are being treated with a medication called Risperidone Long Acting Injectable medication or another antipsychotic medication are candidates for the study. The purpose of the study is to find out from patients' family how they feel the medication has affected their relationship with them. The study will involve meeting with family members three times over the course of one year. The first time will be at New Hampshire Hospital (NHH) or at a community mental health center and the follow up times will be at a convenient place and time for the family member (s), in the community. We will ask them to answer questions from the Family Burden Interview and Quality of Life Questionnaire. The family will not be charged for any test that is completed solely for this study. The family will be provided a travel stipend to meet with the researchers.

Conditions

  • Psychotic Disorders

Interventions

DRUG

Risperdal Long Acting Injectable Antipsychotic Medication

Sponsors & Collaborators

  • Janssen Medical Affairs

    collaborator INDUSTRY

  • National Alliance on Mental Illness New Hampshire

    lead OTHER

Principal Investigators

  • Alex deNesnera, MD · Dartmouth-Hitchcock Medical Center

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2006-02-28
Completion
2006-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00287027 on ClinicalTrials.gov